More

    AstraZeneca shares fall 5% on disappointing lung cancer drug trial



    [

    AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.

    The Covid-19 vaccine maker was trading at the bottom of the FTSE 100 and dragged the wider healthcare sector lower after data published Monday showed that its experimental drug did not significantly improve overall survival results for patients.

    Share were down 4.9% by 9:43 a.m. London time.

    This is a breaking news story. Please check back for updates.

    https://sc.cnbcfm.com/applications/cnbc.com/staticcontent/img/cnbc_logo_new.png?v=1524171804&w=1920&h=1080
    https://www.cnbc.com/2024/09/10/astrazeneca-shares-fall-5percent-on-disappointing-lung-cancer-drug-trial.html

    Latest articles

    spot_imgspot_img

    Related articles

    Leave a reply

    Please enter your comment!
    Please enter your name here

    spot_imgspot_img